MTOR and ovarian cancer: Furthermore, as the mTOR inhibitor BEZ-235 displayed a synergistic effect with cisplatin chemotherapy in vitro, combining mTOR inhibitors with standard-of-care chemotherapy was proposed as a viable option for ovarian cancer patients[67].